Member Info for Mars1

Wonder if LSHS brokered the extension to the rest of NXP001 IP on condition of the acquisition of LSHS as payment therefore capital rather than revenue so significant tax saving.

Older it is probably the case AR did say it was an interim position. I also wonder if he is under pressure from family as he was meant to be non exec which suggests there is a lot more activity atm in the role even though it is progressing two products, suggests there is a lot happening behind the scenes.

FFX the minimum requirement for a plc is 2 directors which NFX still has. A large shareholder (if large enough) can express a vote of no confidence and request a meeting to replace a director with a vote of shareholders, it never usually comes to that. It is more than likely he was fed up with the exec role as it was meant to be temporary.

So was he fed up with the exec role or did Lanstead ask him to go, we will never know. Odd we had two separate successful in vivo studies carried out by different suppliers prior to the one where the protocol failed and then produced inconclusive results. Sounds a bit of a mess should imagine there was a bit of dissatisfaction with the largest shareholder over the tone of the announcement. It is the one inconsistent result through a number of tests.

So they have stated what the next stage is for NXP002 and NXP001 but left us hanging with the next stage for NXP004. With 4 they have told us they have carried further tests they have formulated the drug and they are going to do what?

We might hear about the first patent in July if the US patent office is on schedule, the thing about IP you cannot pick and choose what you want to own, you have to have it all to keep control, so timing will depend upon commitment to the originator whether they feel exposed that another pharma could get there first.

Thanks Older that’s the impression I had it was for me just a question of whether they had implemented their proposed strategy. There are enough confirmations, to me it must be progressing the right way as there has been no other marketing or promotion either with the website or interviews or through internet posts. Unlike NXP002 where if you look for Tranilast updates 002 keeps appearing in the updates.

To put it into context Nexium in the early 2000’s was selling just under $3bn pa this is from the history of AZ;
“ August 2000, Nexium (esomeprazole) for the treatment of acid-related diseases, such as gastrooesophageal reflux disease (GERD), was first launched in Sweden. Between 2001 and 2005, Nexium netted AstraZeneca approximately $14.4 billion”
On those sales avoiding generic competition they saved $2.5bn pa see last note. That gives you an approximate 1 year value for Lynparza where sales are $2.7bn now and rising to $9.7bn.

This article is interesting and shows AZ will switch to a new version of a product;
“ The analysis found that AstraZeneca’s efforts to stop generic competition by releasing and encouraging the use of its new anti-ulcer drug, Nexium, in the early 2000s cost the healthcare system $2,362.9 million a year.”
https://pharmanewsintel.com/news/amp/brand-drug-product-hopping-costs-us-4.7b-annually

Not much before the royalties were subject to the US patent approval. We are in month 21 in June on ave one month away from approvals

Jiving I have posted this before but it deals with a pre-patent protection
https://pharmaphorum.com/news/biogen-protects-tecfidera-1-25bn-deal-forward/

Older confirmed NFX had commenced discussions with AZ after the patent submission in November, no other marketing, so is there some intent, so how long to then notify the market or can AZ take as much time as they want

Jiving yes past performance not ideal however NXP001 was not a blockbuster and development was for a previously untried area. I should imagine independent valuations will be sought and ignored, the difficulty has become with the enormity of the recent approvals. Current sales are $2.7bn with estimates of $9.7bn by 2028, so value is a challenge, this was originally $1bn blockbuster when NFX started. There is no doubt there is significant value to protect market share, I don’t envy their task, but there are industry specialists who value these assets wish one would just state what they think the drug is worth.

It’s easy if AZ does not need patent protection to 2040 then there will be one or two other pharmas wanting to share the $10bn pa market

This is interesting as it gives an insight to the threat of patent expiry as well as commenting on Lynparza
https://pharmaphorum.com/news/az-says-recovery-to-continue-to-despite-patent-expiry-and-brexit-headwinds/

One expires this year and it looks like the balance expire in 2 years time
https://www.drugpatentwatch.com/p/tradename/LYNPARZA

$9+bn revenue pa and rising just what a patent is for to protect market share, auction in 2 months

Merck outperforming re Nasdaq research
https://www.nasdaq.com/articles/merck-mrk-outperforms-industry-this-year-so-far%3A-heres-why?amp

Filter it appears gone are the days the market anticipate s value but as you know over the last 2 to 3 years there has been a constant supply of stock to the market from big holders and when the market knows that they do not have to worry about supply.

I agree 002 is first as it is in play however we are in month 20 of the 004 patent application. This has to be a real worry for AZ/Merck as on average it takes 22 months for patent approval, when that happens how many pharmas would pay to get access to a world top ten drug? The longer they wait the greater the risk that a US pharma will buy the licence or the company.